[Pharmacology of catatonigenic substances. 6. Conclusion].
D000818:Animals; D001060:Aporphines / Q000009:adverse effects / Q000494:pharmacology; D001479:Basal Ganglia / Q000032:analysis / Q000378:metabolism; D001921:Brain / Q000187:drug effects; D002375:Catalepsy / Q000209:etiology; D002389:Catatonia / Q000139:chemically induced*; D002421:Caudate Nucleus / Q000187:drug effects; D002540:Cerebral Cortex / Q000187:drug effects; D004569:Electroencephalography; D006801:Humans; D009020:Morphine / Q000009:adverse effects / Q000494:pharmacology; D010648:Phenylacetates / Q000032:analysis; D011817:Rabbits; D051381:Rats; D012154:Reticular Formation / Q000187:drug effects; D014149:Tranquilizing Agents / Q000009:adverse effects* / Q000494:pharmacology
D001060:Aporphines; D010648:Phenylacetates; D014149:Tranquilizing Agents; D009020:Morphine
Zur Pharmakologie katatonigener Stoffe. 6. Schluss.